Our Pricing

Order Wegovy Privately - No GP Referral Required

Published on: June 03, 2026

When you order Wegovy privately through Cured Pharmacy, you access genuine UK-licensed semaglutide injections without NHS waiting lists or GP referral requirements. Our UK-registered prescribers complete your free clinical assessment in under 3 minutes, with transparent pricing from £79.00 shown upfront before consultation.

How Wegovy (Semaglutide) Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 in your body [1]. This medication works by slowing gastric emptying, reducing appetite signals to the brain, and improving blood sugar regulation — three mechanisms that work together to support significant weight reduction.

In the landmark STEP 1 clinical trial, participants using Wegovy achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. The trial involved 1,961 adults with obesity or overweight with weight-related health conditions, demonstrating consistent results across diverse patient populations.

Semaglutide was originally developed for type 2 diabetes management at lower doses (marketed as Ozempic), but Wegovy delivers higher therapeutic doses specifically licensed by the MHRA for chronic weight management [2]. The once-weekly injection gradually increases from 0.25mg to a maintenance dose of 2.4mg over 16-20 weeks, allowing your body to adjust and minimising gastrointestinal side effects.

Who Can Order Wegovy Privately in the UK

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [3]. During your online consultation, our UK prescribers assess your medical history, current medications, and weight loss goals to determine clinical suitability.

Certain medical conditions require additional consideration before prescribing semaglutide. You should inform your prescriber if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy [3]. Pregnant or breastfeeding women cannot use Wegovy, and the medication should be discontinued at least two months before planned conception.

Unlike NHS pathways that may require 12-month diet and exercise programmes before medication access, private prescriptions through registered UK pharmacies like Cured Pharmacy allow eligible patients to begin treatment immediately following clinical approval. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets MHRA safety standards and GPhC dispensing regulations.

Medical Conditions That May Affect Eligibility

Your prescriber will specifically review contraindications including previous pancreatitis, severe renal impairment, inflammatory bowel disease, and gastroparesis. If you're currently taking other weight loss medications, insulin, or sulfonylureas, dose adjustments may be necessary to prevent hypoglycaemia. Complete disclosure during your consultation ensures safe, personalised prescribing tailored to your clinical profile.

Wegovy Dosing Schedule and What to Expect

Wegovy follows a gradual dose escalation protocol designed to improve gastrointestinal tolerability. You begin with 0.25mg once weekly for four weeks, then increase to 0.5mg for four weeks, followed by 1mg, 1.7mg, and finally the maintenance dose of 2.4mg [2]. Each pen delivers a single pre-measured dose, injected subcutaneously into your abdomen, thigh, or upper arm on the same day each week.

Most patients report the most noticeable appetite reduction within 4-8 weeks of starting treatment, with progressive weight loss continuing throughout the first year [1]. Clinical trials showed that 86% of participants on the 2.4mg maintenance dose achieved at least 5% body weight reduction, and 69% achieved 10% or greater reduction over 68 weeks [1].

Common side effects during dose escalation include nausea, diarrhoea, constipation, and abdominal discomfort, typically mild to moderate and decreasing over time as your body adapts [3]. Taking the injection after eating, staying well-hydrated, and choosing smaller, more frequent meals can help manage these effects. If side effects persist, your prescriber may recommend staying at your current dose for an additional 4 weeks before escalating.

Injection Technique and Storage

Wegovy pens should be stored in the refrigerator between 2°C and 8°C until first use, then can remain at room temperature below 30°C for up to 28 days. Rotate injection sites weekly to prevent lipodystrophy. The pen contains four doses at the 0.25mg and 0.5mg strengths, but only one dose at higher strengths — your prescription will specify the correct pen for your current dose level.

Private Wegovy Prescription Process at Cured Pharmacy

Our streamlined online consultation takes under 3 minutes to complete and covers your medical history, current medications, weight loss history, and treatment goals. Unlike traditional GP appointments that may require multiple visits and referrals, our UK-registered prescribers review your assessment the same day, with most patients receiving prescribing decisions within 24 hours.

Pricing is transparent from the start — you see the exact cost before beginning your consultation, with no hidden fees or surprise charges after prescriber review. Once approved, your prescription is dispensed by our GPhC-registered pharmacy (9012511) and dispatched in 100% discreet packaging via Royal Mail or courier service. Most UK addresses receive delivery within 2-3 working days.

Your treatment includes ongoing clinical support throughout your weight loss journey. If you experience side effects, need dose adjustments, or have questions about your progress, our clinical team remains available by phone (+44 116 4646009) or through your online account. Follow-up consultations for prescription renewals use the same convenient online process, ensuring continuity of care without appointment scheduling delays.

Wegovy vs Other Weight Loss Treatments Available in the UK

Several prescription weight loss medications are licensed in the UK, each working through different mechanisms. Wegovy (semaglutide) is a GLP-1 receptor agonist, while treatments like Orlistat work by blocking fat absorption in the intestines, and Mysimba combines naltrexone and bupropion to reduce appetite through different neural pathways [4].

Saxenda contains liraglutide, an earlier GLP-1 medication requiring daily injections rather than Wegovy's once-weekly dosing [4]. Clinical head-to-head trials showed semaglutide produced greater weight reduction than liraglutide, with the convenience advantage of weekly rather than daily administration [2]. However, some patients may respond better to one GLP-1 formulation than another based on individual metabolism and tolerability.

Newer dual-action treatments like Mounjaro (tirzepatide) activate both GIP and GLP-1 receptors, showing even greater weight loss in clinical trials [5]. Your prescriber considers multiple factors when recommending the most appropriate treatment: your BMI, comorbidities, previous medication responses, injection frequency preference, and clinical trial data relevant to your profile. All injectable weight loss medications available through Cured Pharmacy require the same rigorous clinical assessment and ongoing monitoring.

Combining Wegovy with Lifestyle Modifications

Wegovy is licensed as an adjunct to a reduced-calorie diet and increased physical activity, not as monotherapy [3]. Clinical trials enrolled participants who received nutritional counselling and exercise guidance alongside medication. While semaglutide significantly reduces appetite, establishing sustainable eating patterns and regular movement maximises long-term weight maintenance after treatment completion. Your prescriber can provide resources for evidence-based dietary approaches that complement GLP-1 therapy.

Long-Term Safety and Monitoring for Wegovy Treatment

Semaglutide has been used in clinical practice since 2017 for diabetes management and underwent extensive safety evaluation before MHRA approval for weight management in 2022 [2]. The most serious but rare risks include pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in rodent studies but not conclusively linked in humans) [3]. Your prescriber reviews these risks during consultation and monitors for warning signs throughout treatment.

Regular monitoring during Wegovy treatment should include periodic assessment of heart rate, as GLP-1 receptor agonists can cause modest increases averaging 2-3 beats per minute [3]. Patients with pre-existing cardiovascular conditions require closer monitoring, though the STEP 4 trial demonstrated cardiovascular safety with no increased risk of major adverse cardiac events [6]. If you develop persistent abdominal pain, visual changes, or symptoms of thyroid nodules, contact your prescriber immediately.

Weight loss medications work best as part of comprehensive lifestyle change rather than indefinite pharmaceutical intervention. Clinical data shows that discontinuing Wegovy typically results in gradual weight regain, with participants in the STEP 1 extension regaining approximately two-thirds of lost weight within one year of stopping [1]. Your prescriber discusses realistic treatment duration expectations, transition strategies, and long-term weight maintenance planning as you approach your goal weight. Some patients may benefit from extended treatment, while others successfully maintain losses through sustained behavioural changes after a defined treatment course.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016). Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 315(22), 2424–2434. https://doi.org/10.1001/jama.2016.7602 [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and should only be used under medical supervision as part of a comprehensive weight management programme including diet and exercise.